

Table S1 Subgroup analysis of the associations between 90-day mortality and the RAR level

Variables	No. of patients	RAR			P for interaction
		Q1 (<4.5)	Q2 (4.5–5.7)	Q3 (>5.7)	
Gender					0.13
Male	1059	Ref	1.03 (0.76–1.40)	1.27 (0.91–1.77)	
Female	614	Ref	1.38 (1.08–1.77)	1.52 (1.16–1.99)	
Hypertension					0.10
No	551	Ref	1.19 (0.87–1.62)	1.25 (0.88–1.79)	
Yes	1122	Ref	1.29 (1.01–1.65)	1.49 (1.15–1.94)	
Diabetes					0.45
No	1054	Ref	1.39 (1.09–1.76)	1.48 (1.13–1.93)	
Yes	619	Ref	1.10 (0.79–1.51)	1.26 (0.90–1.78)	
Heart failure					0.007
No	900	Ref	1.11 (0.86–1.44)	1.33 (1.01–1.75)	
Yes	773	Ref	1.39 (1.03–1.87)	1.45 (1.05–2.01)	
Myocardial infarction					0.90
No	1314	Ref	1.26 (1.02–1.56)	1.45 (1.15–1.83)	
Yes	359	Ref	1.09 (0.70–1.72)	1.02 (0.61–1.71)	
Malignant tumour					0.08
No	1483	Ref	1.14 (0.93–1.39)	1.33 (1.07–1.66)	
Yes	190	Ref	3.05 (1.52–6.10)	3.07 (1.41–6.70)	
CKD					0.47
No	1233	Ref	1.19 (0.96–1.48)	1.38 (1.09–1.76)	
Yes	440	Ref	1.51 (0.97–2.35)	1.42 (0.91–2.22)	
AKI					0.001
No	741	Ref	1.35 (1.00–1.83)	1.96 (1.39–2.77)	
Yes	932	Ref	1.12 (0.88–1.44)	1.10 (0.85–1.44)	
Cirrhosis					0.89
No	1554	Ref	1.27 (1.04–1.54)	1.41 (1.14–1.74)	
Yes	119	Ref	0.82 (0.23–2.88)	1.40 (0.44–4.47)	
Anaemia					0.17
No	911	Ref	1.51 (1.33–2.02)	1.64 (1.21–2.22)	
Yes	762	Ref	0.95 (0.73–1.25)	1.28 (0.96–1.72)	
Hepatitis					0.77
No	1604	Ref	1.26 (1.04–1.52)	1.41 (1.14–1.74)	
Yes	69	Ref	1.42 (0.11–17.56)	1.00 (0.09–10.60)	

Table S1 (continued)

Table S1 (continued)

Variables	No. of patients	RAR			P for interaction
		Q1 (<4.5)	Q2 (4.5–5.7)	Q3 (>5.7)	
Pneumonia					0.44
No	934	Ref	1.34 (1.02–1.75)	1.40 (1.05–1.87)	
Yes	739	Ref	1.03 (0.78–1.36)	1.27 (0.94–1.71)	
CPR					0.03
No	1439	Ref	1.31 (1.06–1.61)	1.47 (1.17–1.84)	
Yes	234	Ref	0.80 (0.49–1.32)	0.90 (0.53–1.53)	
Epinephrine					0.40
No	1413	Ref	1.18 (0.96–1.46)	1.41 (1.12–1.77)	
Yes	260	Ref	1.74 (1.00–3.05)	1.37 (0.80–2.35)	
Dobutamine					0.71
No	1588	Ref	1.26 (1.03–1.53)	1.44 (1.16–1.78)	
Yes	85	Ref	0.22 (0.06–0.79)	0.11 (0.02–0.50)	
Dopamine					0.72
No	179	Ref	1.15 (0.63–2.12)	1.00 (0.50–2.01)	
Yes	1494	Ref	1.28 (1.05–1.57)	1.46 (1.17–1.81)	
Norepinephrine					0.03
No	821	Ref	1.16 (0.87–1.53)	1.40 (1.03–1.92)	
Yes	852	Ref	1.25 (0.96–1.64)	1.31 (0.98–1.74)	
Phenylephrine					0.14
No	1292	Ref	1.15 (0.92–1.43)	1.33 (1.05–1.68)	
Yes	381	Ref	1.57 (1.03–2.38)	1.56 (1.00–2.44)	
Milrinone					0.36
No	1598	Ref	1.24 (1.02–1.51)	1.41 (1.14–1.75)	
Yes	75	Ref	0.29 (0.03–3.11)	0.00 (0.00–0.01)	

AKI, acute kidney injury; CKD, chronic kidney disease; CPR, cardiac pulmonary resuscitation; RAR, red blood cell distribution width to albumin ratio.

Table S2 Subgroup analysis of the associations between 28-day mortality and the RAR level

Variables	No. of patients	RAR			P for interaction
		Q1 (<4.5)	Q2 (4.5–5.7)	Q3 (>5.7)	
Gender					0.15
Male	1059	Ref	1.08 (0.77–1.50)	1.21 (0.84–1.74)	
Female	614	Ref	1.40 (1.07–1.82)	1.40 (1.04–1.87)	
Hypertension					0.24
No	551	Ref	1.25 (0.90–1.74)	1.21 (0.83–1.77)	
Yes	1122	Ref	1.32 (1.01–1.73)	1.39 (1.05–1.86)	
Diabetes					0.45
No	1054	Ref	1.42 (1.09–1.83)	1.41 (1.06–1.88)	
Yes	619	Ref	1.14 (0.80–1.61)	1.16 (0.79–1.69)	
Heart failure					0.01
No	900	Ref	1.21 (0.92–1.58)	1.24 (0.92–1.68)	
Yes	773	Ref	1.30 (0.93–1.81)	1.32 (0.92–1.89)	
Myocardial infarction					0.49
No	1314	Ref	1.23 (0.98–1.54)	1.31 (1.02–1.67)	
Yes	359	Ref	1.29 (0.78–2.13)	1.07 (0.60–1.89)	
Malignant tumour					0.08
No	1483	Ref	1.16 (0.93–1.44)	1.24 (0.98–1.58)	
Yes	190	Ref	3.70 (1.72–7.97)	3.25 (1.40–7.56)	
CKD					0.46
No	1233	Ref	1.22 (0.97–1.54)	1.31 (1.01–1.70)	
Yes	440	Ref	1.52 (0.93–2.47)	1.28 (0.78–2.12)	
AKI					0.04
No	741	Ref	1.25 (0.90–1.73)	1.68 (1.16–2.45)	
Yes	932	Ref	1.22 (0.94–1.60)	1.09 (0.81–1.45)	
Cirrhosis					0.83
No	1554	Ref	1.28 (1.04–1.58)	1.29 (1.02–1.63)	
Yes	119	Ref	0.94 (0.19–4.56)	1.71 (0.40–7.22)	
Anaemia					0.06
No	911	Ref	1.71 (1.23–2.38)	1.59 (1.13–2.26)	
Yes	762	Ref	0.93 (0.70–1.23)	1.18 (0.87–1.61)	
Hepatitis					0.58
No	1604	Ref	1.28 (1.04–1.57)	1.32 (1.05–1.66)	
Yes	69	Ref	11.16 (0.44–282.97)	0.51 (0.04–7.00)	

Table S2 (*continued*)

Table S2 (continued)

Variables	No. of patients	RAR			P for interaction
		Q1 (<4.5)	Q2 (4.5–5.7)	Q3 (>5.7)	
Pneumonia					0.40
No	934	Ref	1.38 (1.04–1.83)	1.33 (0.98–1.81)	
Yes	739	Ref	1.04 (0.76–1.41)	1.16 (0.83–1.61)	
CPR					0.09
No	1439	Ref	1.33 (1.06–1.67)	1.39 (1.09–1.78)	
Yes	234	Ref	0.89 (0.52–1.54)	0.78 (0.43–1.41)	
Epinephrine					0.33
No	1413	Ref	1.21 (0.97–1.52)	1.33 (1.04–1.71)	
Yes	260	Ref	1.74 (0.95–3.20)	1.17 (0.65–2.12)	
Dobutamine					0.83
No	1588	Ref	1.27 (1.03–1.57)	1.33 (1.05–1.68)	
Yes	85	Ref	0.25 (0.05–1.16)	0.09 (0.02–0.48)	
Dopamine					0.94
No	179	Ref	1.28 (0.66–2.48)	1.07 (0.51–2.24)	
Yes	1494	Ref	1.29 (1.04–1.61)	1.32 (1.04–1.68)	
Norepinephrine					0.08
No	821	Ref	1.23 (0.90–1.69)	1.31 (0.92–1.86)	
Yes	852	Ref	1.20 (0.90–1.59)	1.15 (0.85–1.56)	
Phenylephrine					0.11
No	1292	Ref	1.18 (0.93–1.49)	1.27 (0.99–1.64)	
Yes	381	Ref	1.49 (0.94–2.34)	1.26 (0.76–2.08)	
Milrinone					0.37
No	1598	Ref	1.28 (1.03–1.58)	1.32 (1.05–1.67)	
Yes	75	Ref	0.00 (0.00–0.00)	0.00 (0.00–0.00)	

AKI, acute kidney injury; CKD, chronic kidney disease; CPR, cardiac pulmonary resuscitation; RAR, red blood cell distribution width to albumin ratio.




Figure S1 Kaplan-Meier survival curves of CA patients stratified by different RAR (RDW to albumin ratio) groups at various prognostic time points; (A) 28-day mortality; (B) 90-day mortality. A higher RAR ratio was significantly associated with higher mortality than a lower RAR ($P < 0.001$).




Figure S2 The restricted cubic spline for the relationships between RAR (RDW to albumin ratio) and different survival outcomes. (A) 28-day mortality in crude model; (B) 28-day mortality in adjusted model 3.




Figure S3 The restricted cubic spline for the relationships between RAR (RDW to albumin ratio) and different survival outcomes. (A) 90-day mortality in crude model; (B) 90-day mortality in adjusted model 3.